中文 | English
Return
Total: 21 , 1/3
Show Home Prev Next End page: GO
Author:(Si-xun PENG)

1.Classification tree model analysis on related factors of early renal damage in type 2 diabetic patients

Wenbo ZHAO ; Ming LI ; Hua TANG ; Xun LIU ; Meijun SI ; Hui PENG ; Tanqi LOU

Chinese Journal of Nephrology 2013;29(8):563-568

2.Proliferation of retinal pigment epithelial cells induced by (R,R)-XY-10 and (S,S)-XY-10 and their action mechanisms

Yu-Wen, CHENG ; Yu-Liang, WANG ; Yi-Hua, ZHANG ; Si-Xun, PENG ; George C Y CHIOU

International Eye Science 2009;9(9):1641-1645

4.A novel class of anti-inflammatory and analgesic drugs--NO-donating NSAIDs.

Yi-hua ZHANG ; Hui JI ; Si-xun PENG

Acta Pharmaceutica Sinica 2007;42(4):352-357

5.Studies on the chemical constituents of Cirsium japonicum DC.

Fei ZHI ; Ling-yi KONG ; Si-xun PENG

Acta Pharmaceutica Sinica 2003;38(6):442-447

6.Advances in the study of nitric oxide-donating drugs.

Yi-hua ZHANG ; Si-xun PENG

Acta Pharmaceutica Sinica 2009;44(11):1200-1210

7.Effects of enantiomers(R,R)-XY and(S,S)-XY on ocular blood flow in rabbits

Jie, PENG ; Yan-Hong, ZOU ; Wei, JIANG ; Xiao-Bin, JI ; Xin-Yu, CHEN ; Yi-Hua, ZHANG ; Si-Xun, PENG ; George C Y CHIOU

International Eye Science 2008;8(3):437-441

8.Effects of ZX-5 and its optical isomers on ocular blood flow in rabbits and retinal function recovery in rats

Jie, PENG ; Yan-Hong, ZOU ; Wei, JIANG ; Yi-Hua, ZHANG ; Xiao-Bin, JI ; Zi-Long, SHEN ; Si-Xun, PENG ; George C Y CHIOU

International Eye Science 2007;7(5):1197-1201

9.Synthesis and antithrombotic activity of acetylsalicyl ferulic acid-coupling furoxans and nitrates.

Zhou ZHOU ; Li-yuan JIANG ; Yi-hua ZHANG ; Hui JI ; Yi SUN ; Si-xun PENG

Acta Pharmaceutica Sinica 2006;41(11):1050-1056

10.Structural characterization of chlorobenzylidine.

Zhong-Hong LI ; Kun-Yi NI ; Guo-Xiong ZHOU ; Can ZHANG ; Wen-Long HUANG ; Si-Xun PENG

Acta Pharmaceutica Sinica 2004;39(7):546-550

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 21 , 1/3 Show Home Prev Next End page: GO